Optimized vaccine candidate MVA-S(3P) fully protects against SARS-CoV-2 infection in hamsters.

Saved in:
Bibliographic Details
Title: Optimized vaccine candidate MVA-S(3P) fully protects against SARS-CoV-2 infection in hamsters.
Authors: Abdelnabi R; Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium., Pérez P; Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain., Astorgano D; Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain., Albericio G; Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain., Kerstens W; Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Translational Platform Virology and Chemotherapy, KU Leuven, Leuven, Belgium., Thibaut HJ; Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Translational Platform Virology and Chemotherapy, KU Leuven, Leuven, Belgium., Coelmont L; Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium., Weynand B; Department of Imaging and Pathology, Translational Cell and Tissue Research, Division of Translational Cell and Tissue Research, KU Leuven, Leuven, Belgium., Labiod N; Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain., Delgado R; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.; Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.; Department of Microbiology, Hospital Universitario 12 de Octubre, Madrid, Spain.; Department of Medicine, Medical School, Universidad Complutense de Madrid, Madrid, Spain., Montenegro D; Biofabri, O Porriño, Pontevedra, Spain., Puentes E; Biofabri, O Porriño, Pontevedra, Spain., Rodríguez E; Biofabri, O Porriño, Pontevedra, Spain., Neyts J; Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium., Dallmeier K; Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium., Esteban M; Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain., García-Arriaza J; Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.
Source: Frontiers in immunology [Front Immunol] 2023 Oct 18; Vol. 14, pp. 1163159. Date of Electronic Publication: 2023 Oct 18 (Print Publication: 2023).
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1664-3224
DOI:10.3389/fimmu.2023.1163159